Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibromun in advanced solid tumors and colorectal cancer
NCT01253837Phase 2Completed
- Sponsor
- Philogen
- Start
- Sep 2007
- Primary completion
- May 2011
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of onfekafusp alfa in solid tumor and colorectal cancer (CRC), sponsored by Philogen. Primary endpoints: Maximum Tolerated Dose and Recommended Dose and Objective Response Rate at day 42. Started Sep 2007; status: completed.
02
Drugs
onfekafusp alfa
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01253837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253837.